Clariant (CLN) CMD 2024 summary
Event summary combining transcript, slides, and related documents.
CMD 2024 summary
8 Jul, 2026Strategic transformation and portfolio focus
Streamlined to a specialty chemicals company with increased consumer market exposure, divesting non-core assets and reducing business units from five to three since 2021, with a flatter structure and full P&L accountability.
Over 90% of CHF 175 million cost savings targeted by 2025 already achieved, with further self-help actions planned to reach CHF 80 million run-rate savings by 2027.
New leadership team based in key growth regions, enhancing local responsiveness and empowerment.
Portfolio now centers on Care Chemicals, Catalysts, and Adsorbents & Additives, each with strong market positions and sustainability focus.
Differentiated segment steering implemented to maximize value creation across business units.
Growth strategy and market positioning
Sales from consumer-facing end markets increased to 44% in Q3 2024, up from 36% in 2021.
Major investments in Asia-Pacific and Americas, with two-thirds of CapEx outside Europe in 2024.
Lucas Meyer Cosmetics acquisition strengthens position in premium active ingredients, targeting 12% annual growth to 2027 and significant synergy potential.
Pharma business targeted for 9% annual growth, leveraging shared chemistry platforms and expansion in Asia.
Digitalization and AI (Clarita/CLARITA) deployed across sales, R&D, and operations, with 36% employee adoption and rising, accelerating innovation and efficiency.
Innovation and sustainability leadership
Over 80% of sales from sustainable products; portfolio now PFAS-free and classified as sustainability positive.
Upgraded 2030 emission reduction targets: 46% for Scope 1 & 2, 28% for Scope 3 upstream, aligned with 1.5°C SBTi trajectory and Paris Agreement.
Top quartile safety and employee engagement achieved; systematic sustainability risk/benefit analysis embedded since 2012.
Three innovation arenas—health & sustainability-conscious consumers, energy transition, and circularity—expected to drive 70% of growth by 2027 and deliver ~1.5% market outgrowth p.a.
AI and digital tools accelerating innovation, with new products accounting for 17.4% of sales and targeted to reach 20% by 2027.
Latest events from Clariant
- Q3 2024 sales fell, but resilient margins support 16% EBITDA margin guidance for 2024.CLN
Q3 20248 Jul 2026 - Sales and margins declined in Q1 2026, but cash flow and cost savings improved amid global challenges.CLN
Q1 202610 May 2026 - EBITDA margin rose to 17.8% in 2025, with flat sales and strong free cash flow conversion.CLN
Q4 20257 Apr 2026 - EBITDA margin before exceptional items rose to 17.9% in Q3 2025 despite lower sales.CLN
Q3 20253 Feb 2026 - EBITDA margin guidance raised to 16% as cost savings and portfolio actions drive resilience.CLN
Q2 20242 Feb 2026 - 2024 delivered higher margins and cash flow; 2025 targets further margin gains and cost savings.CLN
Q4 202426 Dec 2025 - Q1 2025 delivered higher margins and resilient growth, with cautious guidance amid global uncertainty.CLN
Q1 202521 Dec 2025 - EBITDA margin before exceptionals rose to 17.5% in Q2 2025, despite flat sales and restructuring costs.CLN
Q2 202516 Nov 2025 - Clariant advances specialty strategy, boosts margins, and confirms 2024 outlook.CLN
Baader Helvea North America Chemical Roadshow Presentation13 Jun 2025